(CercleFinance.com) – Pfizer announces that it has entered into an agreement to acquire ReViral, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antiviral treatments that target respiratory syncytial virus (RSV).
ReViral has a portfolio of promising therapeutic candidates, including sisunatovir, which has received Fast Track designation from the FDA. RSV is estimated to cause infections resulting in approximately 160,000 deaths worldwide each year.
Pfizer will acquire ReViral for total consideration of up to $525 million. If successful, he estimates annual program revenue from the acquired company could reach or exceed $1.5 billion.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
